Background: Cyclo-oxygenase-2 (COX-2) is induced in cardiomyocytes only in response to stress, such as ischaemia.

Objective: To assess COX-2 expression at the site of recent myocardial infarction.

Methods: COX-2 expression was evaluated by specific immunostaining in cardiomyocytes from 23 subjects who died 10–60 days after acute myocardial infarction. The relation between COX-2 myocardial expression and apoptotic rate was investigated. Cardiomyocyte apoptotic rate was defined as the number of cells co-expressing in situ end labelling of DNA fragmentation (TUNEL) and immunostaining for activated caspase-3.

Results: COX-2 expression was found in cardiomyocytes at the site of infarction in nine of 23 cases (39%). It was associated with fivefold higher apoptotic rates (median 17.9% (interquartile range 11.0–25.4%) v 3.7% (0.6–12.8%); p = 0.016), and apoptotic rate increased progressively from mild to intense COX-2 staining (p for trend 0.009). COX-2 expression co-localised with TUNEL nuclear staining in myocytes, and there was a high concordance between COX-2 and hypoxia induced factor 1-α staining (78%, p = 0.021) and between COX-2 and bax (83%, p = 0.014). Subjects showing myocardial COX-2 expression were more likely to have enlarged hearts (p = 0.050), and intense COX-2 staining was strictly associated with symptomatic heart failure (p = 0.035).

Conclusions: COX-2 is expressed in cardiomyocytes in nearly 40% of cases at the site of recent acute myocardial infarction, even late after the index event. Its expression was associated with extremely high apoptotic rates. These findings suggest a potential cause–effect link between COX-2 expression and enhanced myocardial apoptosis in ischaemic cardiomyopathy.

Cyclo-oxygenase-2 (COX-2) is one of the two isoforms of cyclooxygenase, the rate limiting enzyme in prostaglandin synthesis, catalysing the conversion of arachidonic acid to prostaglandin H2. While cyclo-oxygenase-1 (COX-1) is present in most cells and is responsible for constitutive prostaglandin formation, COX-2 is only induced in cardiomyocytes in response to stress, such as ischaemia, and it is therefore not expressed in healthy myocardium. Myocardial expression of COX-2 has been reported in patients with end stage heart failure; however, extensive data on the presence of COX-2 in cardiomyocytes after acute myocardial infarction are lacking. Moreover, while COX-2 expression has been variably associated with apoptosis in neoplastic disorders and more recently in cerebrovascular disease, there are no available data addressing this issue in the myocardium. Apoptosis may play a central part in the pathophysiology of the acute phases of myocardial infarction as well as in late postinfarction remodelling; it localises to hypoxic regions, and COX-2—which is induced in ischaemia—could have a causal role in the apoptotic cascade.

To assess whether COX-2 expression occurs at the site of recent acute myocardial infarction and whether it is related to cardiomyocyte apoptosis, we used specific immunostaining to study its expression in cardiomyocytes at the time of necropsy from hearts of subjects who died 10 days to two months after acute myocardial infarction and who had no clinical or pathological evidence of reinfarction.

METHODS

Pathology
Twenty three consecutive cases were selected at necropsy. Sampling of the hearts was done in the peri-infarct regions as previously described. Briefly, a gross pathological examination was used to define the infarct area, infarct extension, infarct related artery status, gross indices of cardiac remodelling (transverse and longitudinal diameters, left ventricular free wall thickness, transverse diameter to wall thickness ratio). The clinical characteristics of each patient were obtained from the case records. Heart failure was defined as the presence of signs or symptoms of pulmonary or systemic congestion at rest, as previously described.

COX-2 expression was evaluated using a primary anticox 2 antibody (goat polyclonal sc-1745, Santa Cruz Biotechnology, California, USA) at room temperature for one hour at a 1:100 dilution (according to the results of titration experiments for optimal dilutions), and a secondary reaction using the streptavidin–biotin system (Dako, Carpinteria, California, USA), with diaminobenzidine as the final chromogen. Results were assessed by two independent blinded pathologists on a dichotomic (positive/negative) basis, and positive results were subsequently graded as mild (+) or intense (+++) staining for COX-2, depending on the intensity and extension of the staining; thus a three step scale of COX-2 expression was used: none (−), mild (+), and intense (+++).

The results of the two pathologists were subsequently compared and a consensus reached in all cases. Suitable
positive and negative controls for COX-2 expression were provided, following the manufacturer’s information sheet.

From the total number of cardiomyocytes per optic field, calculated on 100 random fields, cardiomyocyte apoptotic rates were defined as the number of muscle actin positive cells co-expressing in situ end labelling of DNA fragmentation (TUNEL, Apoptag, Oncor, Gaithersburg, Maryland, USA), and immunostaining for activated caspase-3, a terminal effector of the apoptotic cascade (anti-cleaved caspase-3 antibody (Asp 175), Cell Signaling Technology, Beverly, Massachusetts, USA). Positive and negative controls for TUNEL and activated caspase-3 were provided as specified earlier. In particular, cells expressing markers of DNA synthesis (PCNA) and/or RNA splicing (SC-35) were excluded from cell counts to avoid false positive results, and assessment of sensitivity and specificity of the assays employed for TUNEL and caspase-3 was done using human lymph nodes, as described elsewhere.

As additional potential markers of ischaemia, we measured nuclear hypoxia induced factor α (HIF-1α) staining; first, we employed mouse anti-human HIF-1α IgG (IgG2v, Novus Biological, Littleton, Colorado, USA) at 1:100 dilution, according to the supplier’s directions, using a dichotomous positive/negative result; second, we assessed bax cytoplasmic expression (in 12 cases), using a mouse monoclonal anti-human bax sc-7480 from Santa Cruz Biotechnology, Santa Cruz, California, USA, as previously described in detail. Expression was graded as mild or intense, and a human lymph node was used as a control. HIF-1α nuclear staining appears very shortly after the induction of hypoxia and disappears within 10 minutes of restoration of normal oxygen values. It therefore represents a tissue marker for hypoxia, and bax is a central mediator in the mitochondrial, ischaemia induced, caspase-9 dependent apoptotic cascade.

Statistical analysis

For statistical analysis, we used SPSS 10.0 for Windows (SPSS, Chicago, Illinois, USA). Quantitative results are expressed as medians (interquartile range (IQR)). The non-parametric Kruskal–Wallis test and the Mann–Whitney U test for non-paired data were used to compare apoptotic rates among different subjects as appropriate. Logarithmic transformation was used in post-hoc testing for linear trends in univariate analysis of variance (ANOVA). Discrete variables were compared using the non-parametric χ² test.

RESULTS

Patient characteristics and myocardial COX-2 expression

COX-2 expression in cardiomyocytes at the site of recent infarction was found in nine of the 23 cases (39%). In these nine cases, COX-2 staining was observed through the entire peri-infarct region, and uniformly from the epicardial to the endocardial layer, being present in the vast majority of cardiomyocytes. COX-2 expression was mild (+) in three cases (13%) and intense (+++) in the remaining six cases (26%). Figure 1 shows a case of intense COX-2 staining. The clinical characteristics of subjects did not differ between cases with COX-2 myocardial expression and the remainder. The median age of the subjects was 75 years (interquartile range (IQR) 69–81); 13 (56%) were male, and the median time from myocardial infarction to death was 20 days (absolute range 10–62 days) (table 1).

Association between myocardial COX-2 expression and apoptosis late after myocardial infarction

Overall myocardial COX-2 expression was significantly associated with a fivefold higher apoptotic rate (17.9% (11.0–25.4%) for peri-infarct regions with COX-2 expression, vs 3.7% (0.6–12.8%) for those without COX-2 expression; p = 0.016). Apoptotic rates were also increasingly greater when progressing from no COX-2 expression (−) to mild (+) and intense (+++) expression (3.7% (0.6–12.8%), 14.6% (6.4–17.9%), and 24.5% (11.5–26.7%), respectively; p for trend 0.009) (figs 2 and 3). Moreover the vast majority of TUNEL+ cells in COX-2 positive cases showed co-localisation for the two markers (fig 4).

When compared with the other hearts, COX-2 positive hearts showed a greater diameter to wall thickness ratio (12.2 (8.6–13.3) vs 8.7 (7.4–10.5), p = 0.050), which is considered to be a marker of unfavourable postinfarction remodelling. Furthermore, subjects with symptomatic heart failure at the time of their initial hospital admission, or thereafter before death, were more likely to have intense myocardial COX-2 staining (+++) than the others (p = 0.035) (fig 5).

COX-2 expression and markers of ischaemia

The link between ischaemia, COX-2 expression, and apoptosis was strengthened by the finding of intense immunostaining...
in COX-2 positive myocardial regions for both HIF-1α and bax, with a high concordance of COX-2 and HIF-1α expression (74% of cases, p = 0.020), and of COX-2 and bax expression (83%, p = 0.014).

DISCUSSION
These data, despite being limited by the small sample, confirm previous reports of COX-2 expression in ischaemic heart disease, and show for the first time that COX-2 expression in cardiomyocytes occurs 10 days to two months after acute myocardial infarction and is associated with an increased rate of postinfarction myocardial apoptosis. Whether this association reflects a common though independent pathway of ischaemia-driven COX-2 expression and apoptosis, or whether there is a cause–effect link between the two events, is currently unknown and cannot be determined from our data.

COX-2 expression following myocardial and cerebral ischaemia has been shown consistently in experimental models. COX-2 mRNA expression is already induced four hours after ischaemia onset, while COX-2 protein expression peaks at 24 hours. Though COX-2 expression after ischaemic insults in preconditioning animal models has been considered a protective mechanism, several reports have suggested that it plays a detrimental role in cerebral ischaemic damage and apoptosis. Both early and late COX-2 expression after ischaemic brain damage in rats after middle cerebral artery occlusion have been specifically investigated and shown to occur early in the ischaemic regions and late at the infarct border zones. Similarly, Takadera and colleagues have shown upregulation of COX-2 and subsequent enhanced production of COX-2 derived prostaglandin E2 in cerebral ischaemia, and an associated increase in caspase-3 dependent apoptosis. An alternative intriguing hypothesis, however, is to consider COX-2 expression independently from myocardial ischaemia. As an enhanced inflammatory response and neurohumoral activation have been shown to occur after acute myocardial infarction, COX-2 expression in cardiomyocytes—as in other tissues—may be induced in response to such stimuli. Increased COX-2 synthesis may therefore be the expression of a state which itself is associated with increased apoptosis.

Independent of its causes, however, our data showing a significant association between COX-2 expression, myocardial apoptosis, and remodelling suggest that myocardial COX-2 expression in postinfarction remodelling may be detrimental. The resolution of this issue may have profound clinical implications in the light of the prevalence of ischaemic heart disease, the significant role of apoptosis in progression to cardiac failure, and the widespread use of drugs acting on COX-2. Indeed, novel specific COX-2 inhibitors are currently available and may be shown to affect postinfarction cardiac remodelling. Moreover, though retrospective observational studies in humans have been inconclusive, experimental evidence shows that selective inhibition of COX-2 improves cardiac function in a rat model of acute myocardial infarction. Selective COX-2 inhibition appears to be protective against neuronal death after cerebral ischaemia, and in a genetically modified mouse model of non-ischaemic heart failure, COX-2 inhibition was very recently shown to be associated with improved haemodynamics and lower cardiomyocyte apoptotic rates.

Conclusions
The inducible form of cyclo-oxygenase, COX-2, is expressed by cardiomyocytes in nearly 40% of cases at the site of acute myocardial infarction even late after the index event. The expression of COX-2 in postinfarction cardiomyocytes may be detrimental, and remodelling suggest that myocardial COX-2 expression in postinfarction remodelling may be detrimental. The resolution of this issue may have profound clinical implications in the light of the prevalence of ischaemic heart disease, the significant role of apoptosis in progression to cardiac failure, and the widespread use of drugs acting on COX-2. Indeed, novel specific COX-2 inhibitors are currently available and may be shown to affect postinfarction cardiac remodelling. Moreover, though retrospective observational studies in humans have been inconclusive, experimental evidence shows that selective inhibition of COX-2 improves cardiac function in a rat model of acute myocardial infarction. Selective COX-2 inhibition appears to be protective against neuronal death after cerebral ischaemia, and in a genetically modified mouse model of non-ischaemic heart failure, COX-2 inhibition was very recently shown to be associated with improved haemodynamics and lower cardiomyocyte apoptotic rates.
and in this necropsy model of late acute myocardial infarction is associated with extremely high apoptotic rates. These findings suggest a potential link between COX-2 expression and enhanced postinfarction myocardial apoptosis, while the presence of COX-2 in the cytoplasm of cardiomyocytes undergoing apoptosis supports an active role for COX-2 in this process.

Further studies are warranted to investigate the causal role of COX-2 in this association, to evaluate the specific role of ischemia, inflammation, and neurohumoral activation, and to assess the potentially beneficial effect of modulating COX-2 activity.

ACKNOWLEDGEMENTS

We wish to thank Dr Vera Di Trocchio (RomaTre University of Rome, Italy) for her writing, editorial, and graphical support. This study was in part supported by a Futura Onlus grant to AB.

Authors’ affiliations

A Abbate, G G L Biondi-Zoccai, G Liuzzo, F Crea, L M Biasucci, Department of Cardiology, Catholic University, Rome, Italy

S Scarpa, F Vasaturo, Section of Oncology, Campus Bio-Medico University, Rome, Italy

R Bussani, S Silvestri, Department of Anatomic Pathology, University of Trieste, Trieste, Italy

F Baldi, A Baldi, Department of Biochemistry and Biophysics “F Cedrangiolo”, Section of Pathological Anatomy, Second University of Naples, Naples, Italy

REFERENCES


Cyclo-oxygenase-2 (COX-2) expression at the site of recent myocardial infarction: friend or foe?

A Abbate, D Santini, G G L Biondi-Zoccai, S Scarpa, F Vasaturo, G Liuzzo, R Bussani, F Silvestri, F Baldi, F Crea, L M Biasucci and A Baldi

*Heart* 2004 90: 440-443
doi: 10.1136/hrt.2003.010280

Updated information and services can be found at:
http://heart.bmj.com/content/90/4/440

These include:

**References**

This article cites 21 articles, 10 of which you can access for free at:
http://heart.bmj.com/content/90/4/440#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Drugs: cardiovascular system (8842)
- Acute coronary syndromes (2742)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/